Testing a new immunotherapy combo for MSI-H gastric cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) for people with advanced gastric cancer that has a specific DNA repair problem (MSI-H/dMMR). It is for those who have not yet had any treatment for their advanced cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced gastric or gastroesophageal junction cancer that cannot be removed by surgery or has spread.
- Your tumor must have a specific genetic feature called MSI-H or dMMR (a type of DNA repair problem).
- You cannot have received any previous cancer treatment for advanced disease.
- You must be in generally good health (able to care for yourself, with adequate organ function).
- You must be willing to provide a tumor tissue sample from a past or current biopsy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy, anti-angiogenic therapy, and chemotherapy for people with advanced stomach or gastroesophageal junction cancer that hasn't been treated before. It is designed for those whose tumors have low PD-L1 levels.
This trial tests a new drug combination for people with advanced stomach or gastroesophageal junction cancer whose first treatment stopped working. The drugs are designed to help your immune system fight the cancer while chemotherapy attacks it directly.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy (apatinib) and a chemotherapy drug (irinotecan hydrochloride) for people with a rare type of advanced stomach cancer called AFP-producing gastric cancer. It is for patients whose cancer did not respond to previous immunotherapy combined with chemotherapy.
This trial tests a combination of immunotherapy, anti-angiogenic therapy (which cuts off blood supply to tumors), and chemotherapy in people with a specific type of stomach cancer that has certain genetic markers (MSI-H/dMMR). The goal is to see if this combination can make previously inoperable tumors shrink enough for surgery.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with chemotherapy (SOX) and targeted radiation for people with advanced stomach or gastroesophageal junction cancer that hasn't been treated yet. The goal is to see if this approach helps shrink tumors or slow the disease.
This trial tests a combination of two immunotherapy drugs plus chemotherapy as a first treatment for advanced stomach or gastroesophageal junction cancer. The goal is to see if this approach helps shrink tumors and improve survival compared to standard treatment.
Hear when a new Gastric / Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.